Zymeworks (ZYME) has released an update.
Zymeworks Inc., a clinical-stage biotechnology company, announced FDA clearance for their new cancer drug, ZW191, aimed at treating difficult-to-treat cancers including ovarian and non-small cell lung cancer. The drug is designed to target tumors with folate receptor-⍺ expression and has shown promising results in preclinical models with its novel antibody and potent drug-linker. Plans are underway to initiate clinical development in 2024, with filings for regulatory authorization in non-US jurisdictions expected in the latter half of the year.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
